CCI
STML

Columbus Circle Investors’s Stemline Therapeutics, Inc. STML Stock Holding History

Columbus Circle Investors’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-50,000
Closed -$555K – 307
2017
Q3 		$555K Buy
+50,000
New +$470K 0.01% 274

Other funds holding STML

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

Columbus Circle Investors's STML Position: Q4 2017 in Review

Columbus Circle Investors sold out of Stemline Therapeutics, Inc. (STML) in Q4 2017, closing a stake of 284,572 shares — an estimated $3.16M sold.

Columbus Circle Investors first reported a position in STML in Q3 2016 and held it in 5 quarters. The position peaked at $3.16M in Q3 2017. 80 funds tracked by Wall St. Rank hold STML as of Q4 2017.

  • Columbus Circle Investors reported no remaining Stemline Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Columbus Circle Investors sold 284,572 Stemline Therapeutics, Inc. shares in Q4 2017, an estimated $3.16M.
  • Columbus Circle Investors first reported a position in Stemline Therapeutics, Inc. in Q3 2016 and held it in 5 quarters.
  • Columbus Circle Investors's Stemline Therapeutics, Inc. position peaked at $3.16M in Q3 2017.
  • 80 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2017.

Based on Columbus Circle Investors's 13F filing for Q4 2017, filed 2 Feb 2018.